JP2010502651A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502651A5 JP2010502651A5 JP2009526946A JP2009526946A JP2010502651A5 JP 2010502651 A5 JP2010502651 A5 JP 2010502651A5 JP 2009526946 A JP2009526946 A JP 2009526946A JP 2009526946 A JP2009526946 A JP 2009526946A JP 2010502651 A5 JP2010502651 A5 JP 2010502651A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- ring
- heteroalkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- -1 C2-C8 heteroalkenyl Chemical group 0.000 claims 39
- 125000004404 heteroalkyl group Chemical group 0.000 claims 30
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims 11
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 11
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 11
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 11
- 125000002252 acyl group Chemical group 0.000 claims 11
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004429 atom Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 239000012661 PARP inhibitor Substances 0.000 claims 6
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims 4
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 0 *C1NC(*=**)=C(*=C)c2c1c(*)c(*)[s]2 Chemical compound *C1NC(*=**)=C(*=C)c2c1c(*)c(*)[s]2 0.000 description 4
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84206106P | 2006-09-01 | 2006-09-01 | |
| US60/842,061 | 2006-09-01 | ||
| US84454206P | 2006-09-13 | 2006-09-13 | |
| US60/844,542 | 2006-09-13 | ||
| US84668306P | 2006-09-22 | 2006-09-22 | |
| US60/846,683 | 2006-09-22 | ||
| US87393606P | 2006-12-07 | 2006-12-07 | |
| US60/873,936 | 2006-12-07 | ||
| US89571607P | 2007-03-19 | 2007-03-19 | |
| US60/895,716 | 2007-03-19 | ||
| PCT/US2007/077464 WO2008028168A2 (en) | 2006-09-01 | 2007-08-31 | Serine-threonine protein kinase and parp modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010502651A JP2010502651A (ja) | 2010-01-28 |
| JP2010502651A5 true JP2010502651A5 (https=) | 2010-07-29 |
| JP5399905B2 JP5399905B2 (ja) | 2014-01-29 |
Family
ID=39136972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526946A Active JP5399905B2 (ja) | 2006-09-01 | 2007-08-31 | セリン−トレオニンタンパク質キナーゼおよびｐａｒｐ調節因子 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7956064B2 (https=) |
| EP (1) | EP2061765B1 (https=) |
| JP (1) | JP5399905B2 (https=) |
| KR (1) | KR20090050094A (https=) |
| AU (1) | AU2007289065B2 (https=) |
| BR (1) | BRPI0719123A2 (https=) |
| CA (2) | CA2974246C (https=) |
| DK (1) | DK2061765T3 (https=) |
| ES (1) | ES2528316T3 (https=) |
| IL (1) | IL197088A0 (https=) |
| MX (1) | MX2009002298A (https=) |
| NO (1) | NO20090854L (https=) |
| PL (1) | PL2061765T3 (https=) |
| PT (1) | PT2061765E (https=) |
| RU (1) | RU2681209C2 (https=) |
| WO (1) | WO2008028168A2 (https=) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1831225A2 (en) * | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| WO2007114926A2 (en) | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| BRPI0719123A2 (pt) | 2006-09-01 | 2013-12-17 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteína cinase e parp |
| GB2467670B (en) * | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| MX2010007419A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP2011515337A (ja) * | 2008-02-29 | 2011-05-19 | サイレーン ファーマシューティカルズ， インコーポレイテッド | プロテインキナーゼモジュレーター |
| EP2252293B1 (en) * | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US20110212053A1 (en) * | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| BRPI0915231A2 (pt) * | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| BRPI0918846A2 (pt) | 2008-09-02 | 2019-09-24 | Novartis Ag | inibidores de cinase heterocíclica |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| EP2358720B1 (en) | 2008-10-16 | 2016-03-02 | The Regents of The University of California | Fused ring heteroaryl kinase inhibitors |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| AU2009314760B2 (en) * | 2008-11-11 | 2011-11-10 | Je Il Pharmaceutical Co.,Ltd | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| WO2010077530A1 (en) * | 2008-12-17 | 2010-07-08 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
| CN102341107A (zh) * | 2009-01-08 | 2012-02-01 | 赛林药物股份有限公司 | 用于肿瘤疾病的联合治疗 |
| US20100173013A1 (en) * | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
| KR20120044281A (ko) * | 2009-04-17 | 2012-05-07 | 사일린 파마슈티칼스, 인크 | 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법 |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| EP2459561A1 (en) * | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| US20110065698A1 (en) * | 2009-08-26 | 2011-03-17 | Cylene Pharmaceuticals, Inc. | Novel protein kinase modulators |
| US20110071136A1 (en) * | 2009-09-16 | 2011-03-24 | Cylene Pharmaceuticals, Inc | Novel tricyclic protein kinase modulators |
| WO2011041785A1 (en) | 2009-10-02 | 2011-04-07 | Cylene Pharmaceuticals, Inc. | Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| US9216972B2 (en) | 2009-10-29 | 2015-12-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| US8853235B2 (en) * | 2009-11-23 | 2014-10-07 | Senhwa Biosciences, Inc. | Polymorphs and salts of a kinase inhibitor |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
| TWI503323B (zh) | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之ｐｂｋ抑制劑 |
| CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| DE102010025173A1 (de) | 2010-06-25 | 2011-12-29 | Claudia Götz | Verwendung von Dibenzofuranonderivaten zur Inhibierung von Kinasen |
| US20120129849A1 (en) * | 2010-10-22 | 2012-05-24 | Cylene Pharmaceuticals, Inc. | Deuterated serine-threonine protein kinase modulators |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| HK1198443A1 (en) | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| EP2804602B1 (en) | 2012-01-20 | 2024-12-04 | Del Mar Pharmaceuticals | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| JP2015532287A (ja) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｉｒｅ１の調節 |
| AU2013337717B2 (en) | 2012-11-01 | 2018-10-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2935857C (en) | 2014-01-05 | 2020-12-15 | Washington University | Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor |
| MX382033B (es) | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
| MX375707B (es) * | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10213449B2 (en) | 2016-06-16 | 2019-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating medulloblastoma |
| SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
| KR102482825B1 (ko) | 2016-09-02 | 2022-12-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 트리시클릭 헤테로시클릭 화합물 |
| KR20180062804A (ko) * | 2016-12-01 | 2018-06-11 | 사회복지법인 삼성생명공익재단 | 트리시클릭 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 허혈성 급성 신손상 예방 또는 치료용 약학적 조성물 |
| US10040804B2 (en) | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| JP7091336B2 (ja) * | 2016-12-22 | 2022-06-27 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヒストンメチルトランスフェラーゼ阻害剤 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CA3067871A1 (en) * | 2017-07-31 | 2019-02-07 | The Regents Of The University Of California | Benzo[h]isoquinolines and Their Use as Anti-Cancer/Anti-Fibrosis Compounds |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| US11584763B2 (en) | 2017-12-22 | 2023-02-21 | Hibercell, Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| US11071727B2 (en) * | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| CA3116731A1 (en) | 2018-10-19 | 2020-04-23 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
| GB201902759D0 (en) | 2019-02-28 | 2019-04-17 | Benevolentai Bio Ltd | Compositions and uses thereof |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| TW202112784A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2021249224A1 (en) * | 2020-03-30 | 2022-12-01 | Senhwa Biosciences, Inc. | Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis B and hepatitis D |
| GB202102895D0 (en) * | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| US11891395B1 (en) * | 2023-08-25 | 2024-02-06 | King Faisal University | 5-substituted aminopyrazino[2′,1′:2,3]imidazo[4,5-C][2,7]naphthyridine compounds as CK2 inhibitors |
| US12269826B1 (en) * | 2023-11-16 | 2025-04-08 | King Faisal University | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2355084A1 (de) * | 1972-11-06 | 1974-05-16 | Guidotti & C Spa Labor | Verbindungen mit magensaeuresekretionshemmender wirkung und verfahren zu deren herstellung |
| US3859312A (en) * | 1972-12-21 | 1975-01-07 | Richardson Merrell Inc | 6h-dibenzo(b,d)pyran-6-ones |
| JPS5111797A (en) * | 1974-07-18 | 1976-01-30 | Kojin Kk | Shinkina 44 chikanamino 2*66 jiokisoopirido * 3*22c * isokinorinjudotaino seizohoho |
| JPS5377067A (en) * | 1976-12-20 | 1978-07-08 | Teijin Ltd | Preparation of phenanthridone-carboxylic acids |
| JPS53103476A (en) * | 1977-02-18 | 1978-09-08 | Ube Ind Ltd | 6(5h)-phenanthridinone-3,8-dicarboxylic acid and process its preparation |
| US4959361A (en) * | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
| JPH05197241A (ja) | 1992-01-21 | 1993-08-06 | Sharp Corp | 電子写真装置 |
| US5328904A (en) * | 1993-01-27 | 1994-07-12 | Merck & Co., Inc. | 2-phenanthridinyl carbapenem antibacterial agents |
| JP3690825B2 (ja) * | 1993-07-26 | 2005-08-31 | エーザイ株式会社 | 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体 |
| JPH11500100A (ja) * | 1993-09-09 | 1999-01-06 | サイオス ノバ インコーポレイテッド | 偽ペプチドおよび非ペプチドブラジキニンレセプターアンタゴニスト |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| PL189641B1 (pl) * | 1996-11-11 | 2005-09-30 | Altana Pharma Ag | Benzonaftyrydyny, środki farmaceutyczne je zawierające oraz zastosowanie benzonaftyrydyn |
| JPH10282804A (ja) | 1997-04-07 | 1998-10-23 | Ricoh Co Ltd | 画像形成装置 |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| JP2001315103A (ja) * | 2000-05-01 | 2001-11-13 | Harima Chem Inc | 突板化粧合板の製造方法 |
| WO2001090077A1 (en) * | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| JP2002014550A (ja) | 2000-06-30 | 2002-01-18 | Ricoh Co Ltd | 転写装置、転写方法、画像形成装置及び画像形成方法 |
| CZ20031145A3 (cs) * | 2000-10-02 | 2003-12-17 | Janssen Pharmaceutica N.V. | Antagonisté metabotropního glutamátového receptoru |
| JP2002132065A (ja) | 2000-10-23 | 2002-05-09 | Ricoh Co Ltd | 画像形成装置 |
| JP2002156808A (ja) | 2000-11-20 | 2002-05-31 | Ricoh Co Ltd | カラー画像形成装置 |
| JP4323802B2 (ja) * | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
| US20030069295A1 (en) | 2001-08-15 | 2003-04-10 | Gliatech, Inc. | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| US7507727B2 (en) | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
| BRPI0416206A (pt) * | 2003-11-20 | 2006-12-26 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-alquenila e 6-fenilalquila como inibidores de polimerase de poli(adp-ribose) |
| CA2557541C (en) * | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| EP1652841A1 (en) | 2004-04-30 | 2006-05-03 | Switch Biotech Aktiengesellschaft | Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes |
| WO2006034113A2 (en) | 2004-09-17 | 2006-03-30 | Cylene Pharmaceuticals, Inc. | Quinolone analogs as cell proliferation inhibitors |
| US7402579B2 (en) | 2005-04-15 | 2008-07-22 | Cylene Pharmaceuticals, Inc. | Quinobenzoxazine analogs and compositions |
| WO2007051119A1 (en) * | 2005-10-26 | 2007-05-03 | Mgi Gp, Inc. | Methods and compositions of parp inhibitors as potentiators in cancer therapy |
| WO2008016707A2 (en) * | 2006-08-02 | 2008-02-07 | The Johns Hopkins University | Use of il-6 in the diagnosis and treatment of neuroinflammatory conditions |
| BRPI0719123A2 (pt) | 2006-09-01 | 2013-12-17 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteína cinase e parp |
| JP2011515337A (ja) * | 2008-02-29 | 2011-05-19 | サイレーン ファーマシューティカルズ， インコーポレイテッド | プロテインキナーゼモジュレーター |
-
2007
- 2007-08-31 BR BRPI0719123-5A patent/BRPI0719123A2/pt not_active IP Right Cessation
- 2007-08-31 EP EP07841767.2A patent/EP2061765B1/en active Active
- 2007-08-31 PT PT78417672T patent/PT2061765E/pt unknown
- 2007-08-31 DK DK07841767.2T patent/DK2061765T3/en active
- 2007-08-31 CA CA2974246A patent/CA2974246C/en active Active
- 2007-08-31 CA CA2661842A patent/CA2661842C/en active Active
- 2007-08-31 WO PCT/US2007/077464 patent/WO2008028168A2/en not_active Ceased
- 2007-08-31 US US11/849,230 patent/US7956064B2/en active Active
- 2007-08-31 KR KR1020097006608A patent/KR20090050094A/ko not_active Withdrawn
- 2007-08-31 PL PL07841767T patent/PL2061765T3/pl unknown
- 2007-08-31 MX MX2009002298A patent/MX2009002298A/es active IP Right Grant
- 2007-08-31 JP JP2009526946A patent/JP5399905B2/ja active Active
- 2007-08-31 ES ES07841767.2T patent/ES2528316T3/es active Active
- 2007-08-31 AU AU2007289065A patent/AU2007289065B2/en active Active
-
2009
- 2009-02-17 IL IL197088A patent/IL197088A0/en unknown
- 2009-02-25 NO NO20090854A patent/NO20090854L/no not_active Application Discontinuation
-
2011
- 2011-02-25 US US13/035,640 patent/US9062043B2/en active Active
-
2013
- 2013-07-04 RU RU2013130739A patent/RU2681209C2/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502651A5 (https=) | ||
| TWI401255B (zh) | 用以抑制有絲分裂之化合物 | |
| CN108203433B (zh) | 一种rock抑制剂及其应用 | |
| KR102220175B1 (ko) | 헤테로사이클릭 글루타미나아제 억제제 | |
| JP6538656B2 (ja) | ５’−ヌクレオチダーゼ阻害剤およびその治療的使用 | |
| CN110997669B (zh) | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 | |
| EP3104706A1 (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
| JP2021503013A (ja) | Ａｃｓｓ２阻害剤およびその使用方法 | |
| JP2014513078A (ja) | パーキンソン病の治療方法及び治療用組成物 | |
| WO2012041524A1 (en) | Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors | |
| KR20140023886A (ko) | 단백질 키나아제 저해제로서의 인 함유 조성물 | |
| WO2017066193A1 (en) | Novel inhibitors of protein kinases | |
| JP2021505641A (ja) | ＰＰＡＲ−γ調節薬としての新規なベンズアミド誘導体 | |
| KR20180114057A (ko) | 피리미딘 7-원 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물, 및 이의 용도 | |
| CN106660970B (zh) | 喹唑啉衍生物 | |
| NO342001B1 (no) | C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose. | |
| IL293388A (en) | History of benzylamide as a transforming growth factor inhibitor in the i/alk5 receptor cell | |
| CN117643587A (zh) | 用于治疗癌症的杂二环羧酸 | |
| JP2016531947A (ja) | 配座固定されたＰＩ３Ｋ及びｍＴＯＲ阻害剤 | |
| EA037876B1 (ru) | Соединение в виде аминозамещенного шестичленного гетероциклического кольца с гетероатомом азота, его получение и использование | |
| JP6909236B2 (ja) | キナゾリン誘導体またはその塩およびそれを含む医薬組成物 | |
| KR20220105425A (ko) | 티아졸로피리딘 또는 이의 약학적으로 허용 가능한 염 및 이의 용도 | |
| ES2966719T3 (es) | Derivados de quinazolina-2,4-diona como inhibidores de PARP | |
| CN117083265A (zh) | 激酶抑制剂及其用途 | |
| CN109602734A (zh) | 用于治疗白血病的化合物和方法 |